Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.
暂无分享,去创建一个
Patrick Augustijns | Paul J Lewi | Jurgen Joossens | Koen Augustyns | Pieter Van der Veken | J. Heeres | P. Lewi | G. Vanham | P. Augustijns | J. Brouwers | K. Ariën | P. Van der Veken | S. Haenen | J. Joossens | K. Augustyns | M. Venkatraj | Joachim Brouwers | Guido Vanham | Jan Heeres | Kevin K Ariën | Muthusamy Venkatraj | Carolien Grammen | Steven Haenen | C. Grammen
[1] J. Pudney,et al. Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.
[2] John P. Moore,et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. , 2013, The Journal of antimicrobial chemotherapy.
[3] R. Pool,et al. Intravaginal insertion in KwaZulu-Natal: sexual practices and preferences in the context of microbicide gel use , 2010, Culture, health & sexuality.
[4] D. Friend,et al. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. , 2012, AIDS research and human retroviruses.
[5] Lynn Morris,et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.
[6] A. Kashuba,et al. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. , 2012, Best practice & research. Clinical obstetrics & gynaecology.
[7] A. Nel,et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. , 2010, AIDS research and human retroviruses.
[8] C. Dezzutti,et al. Reformulated tenofovir gel for use as a dual compartment microbicide. , 2012, The Journal of antimicrobial chemotherapy.
[9] G. Vanham,et al. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. , 2010, Journal of virological methods.
[10] C. Lacey,et al. Microbicides and HIV prevention: lessons from the past, looking to the future , 2010, Current opinion in infectious diseases.
[11] Eun-Young Kim,et al. Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency Virus , 2005, Journal of Virology.
[12] D. Katz,et al. Design of tenofovir-UC781 combination microbicide vaginal gels. , 2012, Journal of pharmaceutical sciences.
[13] D. Katz,et al. A vaginal fluid simulant. , 1999, Contraception.
[14] R. Pauwels,et al. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. , 2001, Bioorganic & medicinal chemistry letters.
[15] V. Pillay,et al. Qualitative and quantitative intravaginal targeting: key to anti-HIV-1 microbicide delivery from test tube to in vivo success. , 2012, Journal of pharmaceutical sciences.
[16] J. Kaldor,et al. Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting , 2012, BMC Research Notes.
[17] Yunda Huang,et al. In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 Microbicide , 2010, PloS one.
[18] Yanli Liu,et al. Characterization of the inclusion complex of β-cyclodextrin with sorbic acid in the solid state and in aqueous solution , 2010 .
[19] J. Justman,et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women , 2006, AIDS.
[20] G. Doncel,et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. , 2005, AIDS research and human retroviruses.
[21] G. Vanham,et al. In Vitro Evaluation of Viability, Integrity, and Inflammation in Genital Epithelia upon Exposure to Pharmaceutical Excipients and Candidate Microbicides , 2010, Antimicrobial Agents and Chemotherapy.
[22] P. Augustijns,et al. In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients. , 2012, Antiviral research.
[23] Paul J Lewi,et al. Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission. , 2013, The Journal of antimicrobial chemotherapy.